Supriya Life science Wins 8 Gold Awards at Maharashtra State Export Event

Supriya Life science Limited, a global leader in the manufacture of Active Pharmaceutical Ingredients (APIs), has achieved a major achievement by bagging the 8th Gold Award at the Maharashtra State

Mankind Pharma Partners with Lepra Society to Screen 80,000 for Leprosy

Mankind Pharma, an Indian pharmaceutical company, has announced a strategic partnership with the Lepra Society to launch a comprehensive campaign to eradicate, raise awareness, and cure leprosy.

DA Breakthrough Designation for AlphaMedix in Neuroendocrine Tumors

RadioMedix, Inc., a Houston-based clinical technology company and sponsor of the AlphaMedix clinical trial, and Orano Med, a clinical biotechnology company developing next-generation cancer therapies

EURO 2.7M Funding for Phase IIa Trials of CTH120 in Fragile X Syndrome

The public-private group, the biotechnology company CONNECT Therapeutics, the Genome Regulation Center (CRG), the Hospital del Mar Institute (IMIM) and the Parc Taulí Research and Innovation Institute (I3PT) received 2.7 million euros.

Racefor7 Returns: Raising Rare Disease Awareness Feb 25

ORDI (Organization for Rare Diseases of India) will hold its annual flagship conference Racefor7" It will be held in 15 cities across India on February 25.

FDA Fast Track for GSK's Bepirovirsen in Chronic Hepatitis

GSK plc announced that the US Food and Drug Administration (FDA) Fast Track designation for bepirovirsen, an antisense oligonucleotide (ASO) probe for the treatment of chronic hepatitis B (CHB).

Birla Hospital Upgrades OT with Saqsham's Premium Tower 7K for Arthroscopy

CK Birla Hospital, a multi-specialty hospital in Gurgaon sponsored by Saqsham Orthopedics, has installed the ArthroVIMS imaging system for surgeons in its Department of Arthroscopy and Sports Medicine.

Gilead Sciences To Acquire CymaBay For USD 4.3 Billion

U.S. drugmaker Gilead Sciences consented to acquire CymaBay Therapeutics for $4.3 billion, adding a therapy for persistent liver illness to its portfolio. Portions of CymaBay were stopped in front of the declaration in premarket hours...

UK MHRA Approves Comirnaty Omicron XBB.1.5 License Update

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a change of license for Comirnaty Omicron XBB.1.5 30 micrograms/dose (single dose vial) after it was found to meet safety, quality and manager standards of the United King

MedLern and Asha Hospital Collaborate for Training Innovation

MedLern, the only medical education solution for hospitals and healthcare professionals, has entered into a strategic partnership with Asha Hospital, a healthcare facility accredited with NABH,

© 2024 India Pharma Outlook. All Rights Reserved.